Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haidermart Cream is a topical anti-inflammatory and antipruritic cream containing 2% glycyrrhetinic acid. Developed and marketed by Miyarisan Pharmaceutical, it is indicated for the treatment of various inflammatory and pruritic (itchy) skin conditions. Glycyrrhetinic acid, a small molecule derived from licorice root (Glycyrrhiza glabra), is thought to exert its anti-inflammatory effects by inhibiting the enzyme 11β-hydroxysteroid dehydrogenase (11β-HSD). This inhibition prevents the breakdown of endogenous cortisol into its inactive form, cortisone, thereby potentiating the local anti-inflammatory activity of corticosteroids in the skin. The product is distributed in Japan in collaboration with Mayado and Minophagen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Haidermart Cream.